Phacilitate

  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Advanced Therapies Investor Network
    • Women in Advanced Therapies
  • Latest News
Back
  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Advanced Therapies Investor Network
    • Women in Advanced Therapies
  • Latest News
Join Today
Sign In
Sign In
Join Today
  • All Insights and Resources
  • Industry Insights
  • Manufacturing
  • Techniques
Clinical Trials
Collaborations, Mergers and Acquisitions
Finance and Investment
GMP
Patient Access and Engagement
Regulatory and Standards
Reimbursement
Strategy
Automation and Digitisation
Characterisation
CMC
GMP
Logistics
Partnering
Point of Care
Raw Materials
Scaling Up
Skills, Talent and Development
Supply Chain
Allogeneic
Autologous
CAR-X
Cell Therapy
Gene Editing
Gene Therapy
NKx
Stem Cells
Viral/Non-viral Vectors
All News

NKx

FDA RMAT Designation Granted to Fate Therapeutics for FT516 Treatment of Relapsed/Refractory DLBCL
16 December 2021
FDA RMAT Designation Granted to Fate Therapeutics for FT516 Treatment of Relapsed/Refractory DLBCL
News
Strategic Manufacturing Partnership Announced Between Gates Biomanufacturing Facility and Nkarta
6 October 2021
Strategic Manufacturing Partnership Announced Between Gates Biomanufacturing Facility and Nkarta
News
Next-Generation CAR-T, Car-M and NK/NKT Platform Launched, Focussed on Curing Difficult-To-Treat Cancers
16 June 2021
Next-Generation CAR-T, Car-M and NK/NKT Platform Launched, Focussed on Curing Difficult-To-Treat Cancers
Inceptor Bio has announced the
Research Collaboration Seeks to Optimise Dual-Targeted NK Cell Therapy Against Acute Myeloid Leukaemia
26 May 2021
Research Collaboration Seeks to Optimise Dual-Targeted NK Cell Therapy Against Acute Myeloid Leukaemia
A new research agreement, funded
POPULAR NEWS ITEMS
Image
26 May 2022

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image
25 May 2022

Key Takeaways from ASGCT 2022

Image
24 May 2022

Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation in vivo CAR-T

Enabling Next Generation Cell Therapies with GMP-Grade Human iPSCs
3 March 2021
Enabling Next Generation Cell Therapies with GMP-Grade Human iPSCs
Are induced pluripotent stem cells
Harnessing the Power of the Innate Immune System Using NK Cells
8 January 2019
Harnessing the Power of the Innate Immune System Using NK Cells
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image

Key Takeaways from ASGCT 2022

Image

Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation in vivo CAR-T

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022